| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Akebia Therapeutics, Inc. (AKBA) has 10 insiders with recent SEC Form 4 filings, including 3 buys and 8 sells. AKBA is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.46M | $4.02M | - | |
| CFO | 320.0K | $371.2K | - | |
| Dir | 160.9K | $186.7K | - | |
| Dir | 129.5K | $150.2K | - | |
| VP | 119.0K | $138.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 20, 2019 | Smith Cynthia | Director | Buy | 15,000 | $3.52 | $52,800.00 | +109.5% | |
| Nov 20, 2019 | Gilman Steven C70 | Director | Buy | 5,800 | $3.43 | $19,894.00 | +24.2% | |
| Feb 15, 2018 | Nash Duane | Director | Sell | 1,000 | $14.62 | $14,620.00 | -4.4% | |
| Oct 2, 2017 | Nash Duane | Director | Sell | 1,188 | $19.64 | $23,332.32 | -5.0% | |
| Oct 2, 2017 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 7,803 | $19.89 | $155,188.42 | -3.6% | |
| Oct 2, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,398 | $19.64 | $27,456.72 | -1.4% | |
| Sep 28, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 5,000 | $19.30 | $96,500.00 | -4.9% | |
| Aug 15, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 5,000 | $15.00 | $75,000.00 | -4.7% | |
| Jul 5, 2017 | Satter Muneer A58 | Director | Buy | 1,034,482 | $14.50 | $14,999,989.00 | +51.7% | |
| Jul 3, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,399 | $14.26 | $19,946.52 | -1.3% |